botensilimab

Agenus Shifts Focus to CTLA-4/PD-1 Combo Treatment, Implementing Layoffs and Pipeline Refinement

Agenus, an immuno-oncology firm, is reshaping its strategy to prioritize its CTLA-4/PD-1 combo treatment while temporarily redirecting its unpartnered programs. ...